top of page
All News
Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorizationAdvancing faster access to a much-needed new treatment for gonorrhoea
The GARDP Foundation (known as GARDP) and Dr. Reddy's Laboratories today announced that the Thai Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea. The approval follows a priority review submission led by Dr. Reddy's Laboratories, with support from GARDP. NUZOLVENCE® is indicated for the treatment of uncomplicated urogenital gonorrhoea due to Neisseria gonorrhoe
Jul 284 min read
bottom of page